Key Takeaways
- • Johnson & Johnson MedTech is in active negotiations with Apollo Global Management to sell all or a portion of its DePuy Synthes orthopedics business, with deal valuation estimated at approximately $20 billion.
- • DePuy Synthes generated $9.3 billion in revenue during 2025, representing more than 25% of J&J MedTech's $33.8 billion total revenue, but has been the slowest-growing segment with only 1.1% year-over-year sales growth in the most recent fiscal year.
- • J&J announced plans in late 2025 to separate DePuy Synthes into a standalone entity, with completion targeted for mid-2027; a potential sale to Apollo would represent a strategic pivot from this previously disclosed separation strategy.
- • The divestiture aligns with J&J MedTech's strategic shift toward higher-growth businesses, particularly Cardiovascular, which delivered 8.3% revenue growth in the first half of 2026 following major acquisitions including Shockwave Medical ($13.1 billion in 2024) and Abiomed ($16.6 billion in 2022).
Summary
Johnson & Johnson MedTech is negotiating with Apollo Global Management regarding the potential sale of its DePuy Synthes orthopedics business, marking a significant strategic reassessment of the company's portfolio. According to Bloomberg and The Wall Street Journal reports citing anonymous sources, the transaction could value DePuy Synthes at approximately $20 billion, with discussions covering either a full sale or a partial stake transfer. The Wall Street Journal specifically identified the hips and knees segment as part of the negotiated assets.
The proposed transaction would represent a material corporate action. DePuy Synthes contributed $9.3 billion in revenue during 2025, accounting for more than one-quarter of J&J MedTech's total $33.8 billion in annual revenue. However, the business has underperformed relative to other J&J MedTech divisions, generating only 1.1% year-over-year revenue growth in the most recent fiscal year—a significant drag on consolidated performance.
This sale discussion follows J&J MedTech's December 2025 announcement of plans to separate DePuy Synthes into an independent public company, with separation targeted for mid-2027. A February 2026 Bloomberg report indicated that large private equity firms were positioning to acquire such an asset in a roughly $20 billion transaction. The current Apollo negotiations appear to represent a strategic evolution, potentially accelerating the divestiture timeline through an outright sale to private equity rather than a standalone IPO.
J&J MedTech's strategic focus has increasingly shifted toward higher-growth orthopedic segments and other business units. The Cardiovascular division led growth metrics with 8.3% revenue expansion during the first half of 2026, driven by strategic acquisitions including Shockwave Medical (acquired for $13.1 billion in 2024) and Abiomed (acquired for $16.6 billion in 2022). Most recently, J&J achieved FDA approval over the summer for its dual-energy ThermoCool SmartTouch SF ablation platform, expanding its atrial fibrillation treatment capabilities.
The potential DePuy Synthes transaction would unlock capital while allowing J&J MedTech to concentrate resources and investment on faster-growing segments. Apollo Global Management's interest in the orthopedics business reflects the private equity firm's confidence in the asset's cash generation capabilities and operational improvement potential, though sources note that negotiations do not guarantee transaction completion.
The proposed transaction would represent a material corporate action. DePuy Synthes contributed $9.3 billion in revenue during 2025, accounting for more than one-quarter of J&J MedTech's total $33.8 billion in annual revenue. However, the business has underperformed relative to other J&J MedTech divisions, generating only 1.1% year-over-year revenue growth in the most recent fiscal year—a significant drag on consolidated performance.
This sale discussion follows J&J MedTech's December 2025 announcement of plans to separate DePuy Synthes into an independent public company, with separation targeted for mid-2027. A February 2026 Bloomberg report indicated that large private equity firms were positioning to acquire such an asset in a roughly $20 billion transaction. The current Apollo negotiations appear to represent a strategic evolution, potentially accelerating the divestiture timeline through an outright sale to private equity rather than a standalone IPO.
J&J MedTech's strategic focus has increasingly shifted toward higher-growth orthopedic segments and other business units. The Cardiovascular division led growth metrics with 8.3% revenue expansion during the first half of 2026, driven by strategic acquisitions including Shockwave Medical (acquired for $13.1 billion in 2024) and Abiomed (acquired for $16.6 billion in 2022). Most recently, J&J achieved FDA approval over the summer for its dual-energy ThermoCool SmartTouch SF ablation platform, expanding its atrial fibrillation treatment capabilities.
The potential DePuy Synthes transaction would unlock capital while allowing J&J MedTech to concentrate resources and investment on faster-growing segments. Apollo Global Management's interest in the orthopedics business reflects the private equity firm's confidence in the asset's cash generation capabilities and operational improvement potential, though sources note that negotiations do not guarantee transaction completion.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.